RBC Capital lowered the firm’s price target on Neurocrine (NBIX) to $148 from $154 and keeps a Sector Perform rating on the shares. The company’s weak Q4 sales and lower-than-anticipated 2025 Ingrezza guidance, coupled with limited color on and measured expectations for Crenessity, will likely lead to some disappointment, and while the potential long-term risks were well known, this likely introduces more near-term base business uncertainty than expected, the analyst tells investors in a research note.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target lowered to $185 from $190 at H.C. Wainwright
- Neurocrine price target lowered to $179 from $184 at BofA
- Neurocrine price target lowered to $163 from $172 at Canaccord
- Neurocrine Biosciences Reports Strong Growth in 2024
- Closing Bell Movers: Amazon slips 4% on soft Q1 outlook, capex plans